nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—CYP3A4—bone cancer	0.507	1	CbGaD
Sirolimus—SLCO1B1—Methotrexate—bone cancer	0.017	0.455	CbGbCtD
Sirolimus—ABCB1—Cisplatin—bone cancer	0.00749	0.201	CbGbCtD
Sirolimus—MTOR—leg—bone cancer	0.00515	0.161	CbGeAlD
Sirolimus—MTOR—forelimb—bone cancer	0.00511	0.16	CbGeAlD
Sirolimus—ABCB1—Doxorubicin—bone cancer	0.00502	0.134	CbGbCtD
Sirolimus—ABCB1—Methotrexate—bone cancer	0.00486	0.13	CbGbCtD
Sirolimus—MTOR—hindlimb—bone cancer	0.0046	0.144	CbGeAlD
Sirolimus—MTOR—appendage—bone cancer	0.00395	0.123	CbGeAlD
Sirolimus—CYP3A4—Doxorubicin—bone cancer	0.00301	0.0805	CbGbCtD
Sirolimus—EIF4E—connective tissue—bone cancer	0.00291	0.0908	CbGeAlD
Sirolimus—Pimecrolimus—CYP3A4—bone cancer	0.00197	0.306	CrCbGaD
Sirolimus—Everolimus—CYP3A4—bone cancer	0.00197	0.306	CrCbGaD
Sirolimus—Temsirolimus—CYP3A4—bone cancer	0.00133	0.207	CrCbGaD
Sirolimus—FGF2—tendon—bone cancer	0.00122	0.0381	CbGeAlD
Sirolimus—FGF2—spinal cord—bone cancer	0.00118	0.0367	CbGeAlD
Sirolimus—Tacrolimus—CYP3A4—bone cancer	0.00117	0.182	CrCbGaD
Sirolimus—MTOR—connective tissue—bone cancer	0.00113	0.0351	CbGeAlD
Sirolimus—FKBP1A—connective tissue—bone cancer	0.00101	0.0316	CbGeAlD
Sirolimus—MTOR—tendon—bone cancer	0.000774	0.0242	CbGeAlD
Sirolimus—MTOR—bone marrow—bone cancer	0.00075	0.0234	CbGeAlD
Sirolimus—MTOR—spinal cord—bone cancer	0.000747	0.0233	CbGeAlD
Sirolimus—FKBP1A—tendon—bone cancer	0.000696	0.0217	CbGeAlD
Sirolimus—FKBP1A—bone marrow—bone cancer	0.000674	0.021	CbGeAlD
Sirolimus—FKBP1A—spinal cord—bone cancer	0.000671	0.021	CbGeAlD
Sirolimus—SLC47A1—tendon—bone cancer	0.000598	0.0187	CbGeAlD
Sirolimus—SLC47A1—spinal cord—bone cancer	0.000577	0.018	CbGeAlD
Sirolimus—Pancreatitis—Doxorubicin—bone cancer	0.000211	0.000817	CcSEcCtD
Sirolimus—Weight decreased—Epirubicin—bone cancer	0.000211	0.000814	CcSEcCtD
Sirolimus—Hyperglycaemia—Epirubicin—bone cancer	0.00021	0.000812	CcSEcCtD
Sirolimus—Hepatobiliary disease—Methotrexate—bone cancer	0.00021	0.000811	CcSEcCtD
Sirolimus—Epistaxis—Methotrexate—bone cancer	0.000209	0.000809	CcSEcCtD
Sirolimus—Pneumonia—Epirubicin—bone cancer	0.000209	0.000807	CcSEcCtD
Sirolimus—Infestation NOS—Epirubicin—bone cancer	0.000208	0.000803	CcSEcCtD
Sirolimus—Infestation—Epirubicin—bone cancer	0.000208	0.000803	CcSEcCtD
Sirolimus—Bronchitis—Doxorubicin—bone cancer	0.000207	0.000801	CcSEcCtD
Sirolimus—Pancytopenia—Doxorubicin—bone cancer	0.000205	0.000791	CcSEcCtD
Sirolimus—Body temperature increased—Cisplatin—bone cancer	0.000204	0.000788	CcSEcCtD
Sirolimus—Neuropathy peripheral—Epirubicin—bone cancer	0.000204	0.000787	CcSEcCtD
Sirolimus—Stomatitis—Epirubicin—bone cancer	0.000202	0.000782	CcSEcCtD
Sirolimus—Conjunctivitis—Epirubicin—bone cancer	0.000202	0.00078	CcSEcCtD
Sirolimus—Urinary tract infection—Epirubicin—bone cancer	0.000202	0.00078	CcSEcCtD
Sirolimus—Neutropenia—Doxorubicin—bone cancer	0.000202	0.000779	CcSEcCtD
Sirolimus—Dysuria—Doxorubicin—bone cancer	0.000202	0.000779	CcSEcCtD
Sirolimus—Upper respiratory tract infection—Doxorubicin—bone cancer	0.0002	0.000774	CcSEcCtD
Sirolimus—Haemoglobin—Methotrexate—bone cancer	0.0002	0.000774	CcSEcCtD
Sirolimus—Haemorrhage—Methotrexate—bone cancer	0.000199	0.00077	CcSEcCtD
Sirolimus—Sweating—Epirubicin—bone cancer	0.000199	0.000769	CcSEcCtD
Sirolimus—Pollakiuria—Doxorubicin—bone cancer	0.000199	0.000769	CcSEcCtD
Sirolimus—Haematuria—Epirubicin—bone cancer	0.000198	0.000765	CcSEcCtD
Sirolimus—Pharyngitis—Methotrexate—bone cancer	0.000198	0.000764	CcSEcCtD
Sirolimus—Urinary tract disorder—Methotrexate—bone cancer	0.000197	0.00076	CcSEcCtD
Sirolimus—Hepatobiliary disease—Epirubicin—bone cancer	0.000196	0.000759	CcSEcCtD
Sirolimus—Weight increased—Doxorubicin—bone cancer	0.000196	0.000758	CcSEcCtD
Sirolimus—Epistaxis—Epirubicin—bone cancer	0.000196	0.000757	CcSEcCtD
Sirolimus—Urethral disorder—Methotrexate—bone cancer	0.000195	0.000755	CcSEcCtD
Sirolimus—Weight decreased—Doxorubicin—bone cancer	0.000195	0.000754	CcSEcCtD
Sirolimus—Sinusitis—Epirubicin—bone cancer	0.000195	0.000753	CcSEcCtD
Sirolimus—Hyperglycaemia—Doxorubicin—bone cancer	0.000194	0.000751	CcSEcCtD
Sirolimus—Pneumonia—Doxorubicin—bone cancer	0.000193	0.000747	CcSEcCtD
Sirolimus—Infestation—Doxorubicin—bone cancer	0.000192	0.000743	CcSEcCtD
Sirolimus—Infestation NOS—Doxorubicin—bone cancer	0.000192	0.000743	CcSEcCtD
Sirolimus—Visual impairment—Methotrexate—bone cancer	0.000192	0.000742	CcSEcCtD
Sirolimus—Hypersensitivity—Cisplatin—bone cancer	0.00019	0.000734	CcSEcCtD
Sirolimus—Neuropathy peripheral—Doxorubicin—bone cancer	0.000188	0.000728	CcSEcCtD
Sirolimus—Haemoglobin—Epirubicin—bone cancer	0.000187	0.000724	CcSEcCtD
Sirolimus—Stomatitis—Doxorubicin—bone cancer	0.000187	0.000724	CcSEcCtD
Sirolimus—Rhinitis—Epirubicin—bone cancer	0.000187	0.000722	CcSEcCtD
Sirolimus—Conjunctivitis—Doxorubicin—bone cancer	0.000187	0.000722	CcSEcCtD
Sirolimus—Urinary tract infection—Doxorubicin—bone cancer	0.000187	0.000722	CcSEcCtD
Sirolimus—Haemorrhage—Epirubicin—bone cancer	0.000186	0.000721	CcSEcCtD
Sirolimus—Tinnitus—Methotrexate—bone cancer	0.000186	0.000718	CcSEcCtD
Sirolimus—Hypoaesthesia—Epirubicin—bone cancer	0.000185	0.000717	CcSEcCtD
Sirolimus—Asthenia—Cisplatin—bone cancer	0.000185	0.000715	CcSEcCtD
Sirolimus—Pharyngitis—Epirubicin—bone cancer	0.000185	0.000715	CcSEcCtD
Sirolimus—Cardiac disorder—Methotrexate—bone cancer	0.000185	0.000715	CcSEcCtD
Sirolimus—Sweating—Doxorubicin—bone cancer	0.000184	0.000712	CcSEcCtD
Sirolimus—Urinary tract disorder—Epirubicin—bone cancer	0.000184	0.000712	CcSEcCtD
Sirolimus—Oedema peripheral—Epirubicin—bone cancer	0.000184	0.00071	CcSEcCtD
Sirolimus—Haematuria—Doxorubicin—bone cancer	0.000183	0.000708	CcSEcCtD
Sirolimus—Connective tissue disorder—Epirubicin—bone cancer	0.000183	0.000708	CcSEcCtD
Sirolimus—Urethral disorder—Epirubicin—bone cancer	0.000183	0.000706	CcSEcCtD
Sirolimus—Hepatobiliary disease—Doxorubicin—bone cancer	0.000182	0.000702	CcSEcCtD
Sirolimus—Epistaxis—Doxorubicin—bone cancer	0.000181	0.0007	CcSEcCtD
Sirolimus—Angiopathy—Methotrexate—bone cancer	0.000181	0.000699	CcSEcCtD
Sirolimus—Sinusitis—Doxorubicin—bone cancer	0.00018	0.000697	CcSEcCtD
Sirolimus—Immune system disorder—Methotrexate—bone cancer	0.00018	0.000695	CcSEcCtD
Sirolimus—Visual impairment—Epirubicin—bone cancer	0.00018	0.000694	CcSEcCtD
Sirolimus—Mediastinal disorder—Methotrexate—bone cancer	0.00018	0.000694	CcSEcCtD
Sirolimus—Chills—Methotrexate—bone cancer	0.000179	0.000691	CcSEcCtD
Sirolimus—Diarrhoea—Cisplatin—bone cancer	0.000176	0.000682	CcSEcCtD
Sirolimus—Tinnitus—Epirubicin—bone cancer	0.000174	0.000672	CcSEcCtD
Sirolimus—Malnutrition—Methotrexate—bone cancer	0.000173	0.00067	CcSEcCtD
Sirolimus—Haemoglobin—Doxorubicin—bone cancer	0.000173	0.00067	CcSEcCtD
Sirolimus—Cardiac disorder—Epirubicin—bone cancer	0.000173	0.000669	CcSEcCtD
Sirolimus—Rhinitis—Doxorubicin—bone cancer	0.000173	0.000668	CcSEcCtD
Sirolimus—Haemorrhage—Doxorubicin—bone cancer	0.000172	0.000667	CcSEcCtD
Sirolimus—Hypoaesthesia—Doxorubicin—bone cancer	0.000172	0.000663	CcSEcCtD
Sirolimus—Pharyngitis—Doxorubicin—bone cancer	0.000171	0.000662	CcSEcCtD
Sirolimus—Urinary tract disorder—Doxorubicin—bone cancer	0.00017	0.000658	CcSEcCtD
Sirolimus—Oedema peripheral—Doxorubicin—bone cancer	0.00017	0.000657	CcSEcCtD
Sirolimus—Connective tissue disorder—Doxorubicin—bone cancer	0.000169	0.000655	CcSEcCtD
Sirolimus—Angiopathy—Epirubicin—bone cancer	0.000169	0.000654	CcSEcCtD
Sirolimus—Urethral disorder—Doxorubicin—bone cancer	0.000169	0.000654	CcSEcCtD
Sirolimus—Immune system disorder—Epirubicin—bone cancer	0.000168	0.000651	CcSEcCtD
Sirolimus—Mediastinal disorder—Epirubicin—bone cancer	0.000168	0.000649	CcSEcCtD
Sirolimus—Back pain—Methotrexate—bone cancer	0.000168	0.000648	CcSEcCtD
Sirolimus—Chills—Epirubicin—bone cancer	0.000167	0.000646	CcSEcCtD
Sirolimus—Visual impairment—Doxorubicin—bone cancer	0.000166	0.000642	CcSEcCtD
Sirolimus—Vomiting—Cisplatin—bone cancer	0.000164	0.000634	CcSEcCtD
Sirolimus—Rash—Cisplatin—bone cancer	0.000163	0.000628	CcSEcCtD
Sirolimus—Dermatitis—Cisplatin—bone cancer	0.000162	0.000628	CcSEcCtD
Sirolimus—Malnutrition—Epirubicin—bone cancer	0.000162	0.000627	CcSEcCtD
Sirolimus—Ill-defined disorder—Methotrexate—bone cancer	0.000161	0.000622	CcSEcCtD
Sirolimus—Tinnitus—Doxorubicin—bone cancer	0.000161	0.000622	CcSEcCtD
Sirolimus—Anaemia—Methotrexate—bone cancer	0.00016	0.000619	CcSEcCtD
Sirolimus—Cardiac disorder—Doxorubicin—bone cancer	0.00016	0.000619	CcSEcCtD
Sirolimus—Flatulence—Epirubicin—bone cancer	0.00016	0.000618	CcSEcCtD
Sirolimus—Tension—Epirubicin—bone cancer	0.000159	0.000615	CcSEcCtD
Sirolimus—Nervousness—Epirubicin—bone cancer	0.000158	0.000609	CcSEcCtD
Sirolimus—Back pain—Epirubicin—bone cancer	0.000157	0.000607	CcSEcCtD
Sirolimus—Angiopathy—Doxorubicin—bone cancer	0.000156	0.000605	CcSEcCtD
Sirolimus—Malaise—Methotrexate—bone cancer	0.000156	0.000604	CcSEcCtD
Sirolimus—Muscle spasms—Epirubicin—bone cancer	0.000156	0.000603	CcSEcCtD
Sirolimus—ABCB1—bone marrow—bone cancer	0.000156	0.00487	CbGeAlD
Sirolimus—Immune system disorder—Doxorubicin—bone cancer	0.000156	0.000602	CcSEcCtD
Sirolimus—Mediastinal disorder—Doxorubicin—bone cancer	0.000155	0.000601	CcSEcCtD
Sirolimus—ABCB1—spinal cord—bone cancer	0.000155	0.00485	CbGeAlD
Sirolimus—Leukopenia—Methotrexate—bone cancer	0.000155	0.0006	CcSEcCtD
Sirolimus—Chills—Doxorubicin—bone cancer	0.000155	0.000598	CcSEcCtD
Sirolimus—Nausea—Cisplatin—bone cancer	0.000153	0.000592	CcSEcCtD
Sirolimus—Cough—Methotrexate—bone cancer	0.000151	0.000585	CcSEcCtD
Sirolimus—Ill-defined disorder—Epirubicin—bone cancer	0.000151	0.000582	CcSEcCtD
Sirolimus—Malnutrition—Doxorubicin—bone cancer	0.00015	0.00058	CcSEcCtD
Sirolimus—Anaemia—Epirubicin—bone cancer	0.00015	0.00058	CcSEcCtD
Sirolimus—Agitation—Epirubicin—bone cancer	0.000149	0.000576	CcSEcCtD
Sirolimus—Flatulence—Doxorubicin—bone cancer	0.000148	0.000572	CcSEcCtD
Sirolimus—Arthralgia—Methotrexate—bone cancer	0.000148	0.000571	CcSEcCtD
Sirolimus—Myalgia—Methotrexate—bone cancer	0.000148	0.000571	CcSEcCtD
Sirolimus—Chest pain—Methotrexate—bone cancer	0.000148	0.000571	CcSEcCtD
Sirolimus—Tension—Doxorubicin—bone cancer	0.000147	0.000569	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000147	0.000567	CcSEcCtD
Sirolimus—Malaise—Epirubicin—bone cancer	0.000146	0.000566	CcSEcCtD
Sirolimus—Discomfort—Methotrexate—bone cancer	0.000146	0.000564	CcSEcCtD
Sirolimus—Nervousness—Doxorubicin—bone cancer	0.000146	0.000564	CcSEcCtD
Sirolimus—Syncope—Epirubicin—bone cancer	0.000146	0.000562	CcSEcCtD
Sirolimus—Leukopenia—Epirubicin—bone cancer	0.000145	0.000561	CcSEcCtD
Sirolimus—Back pain—Doxorubicin—bone cancer	0.000145	0.000561	CcSEcCtD
Sirolimus—Muscle spasms—Doxorubicin—bone cancer	0.000144	0.000558	CcSEcCtD
Sirolimus—Palpitations—Epirubicin—bone cancer	0.000143	0.000554	CcSEcCtD
Sirolimus—Confusional state—Methotrexate—bone cancer	0.000143	0.000552	CcSEcCtD
Sirolimus—Loss of consciousness—Epirubicin—bone cancer	0.000143	0.000551	CcSEcCtD
Sirolimus—Cough—Epirubicin—bone cancer	0.000142	0.000547	CcSEcCtD
Sirolimus—Anaphylactic shock—Methotrexate—bone cancer	0.000142	0.000547	CcSEcCtD
Sirolimus—Infection—Methotrexate—bone cancer	0.000141	0.000543	CcSEcCtD
Sirolimus—Hypertension—Epirubicin—bone cancer	0.00014	0.000542	CcSEcCtD
Sirolimus—Ill-defined disorder—Doxorubicin—bone cancer	0.000139	0.000538	CcSEcCtD
Sirolimus—Nervous system disorder—Methotrexate—bone cancer	0.000139	0.000536	CcSEcCtD
Sirolimus—Anaemia—Doxorubicin—bone cancer	0.000139	0.000536	CcSEcCtD
Sirolimus—Thrombocytopenia—Methotrexate—bone cancer	0.000139	0.000536	CcSEcCtD
Sirolimus—Arthralgia—Epirubicin—bone cancer	0.000138	0.000534	CcSEcCtD
Sirolimus—Myalgia—Epirubicin—bone cancer	0.000138	0.000534	CcSEcCtD
Sirolimus—Chest pain—Epirubicin—bone cancer	0.000138	0.000534	CcSEcCtD
Sirolimus—Agitation—Doxorubicin—bone cancer	0.000138	0.000533	CcSEcCtD
Sirolimus—Anxiety—Epirubicin—bone cancer	0.000138	0.000532	CcSEcCtD
Sirolimus—Skin disorder—Methotrexate—bone cancer	0.000137	0.000531	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000137	0.00053	CcSEcCtD
Sirolimus—Hyperhidrosis—Methotrexate—bone cancer	0.000137	0.000529	CcSEcCtD
Sirolimus—Discomfort—Epirubicin—bone cancer	0.000137	0.000528	CcSEcCtD
Sirolimus—Malaise—Doxorubicin—bone cancer	0.000135	0.000523	CcSEcCtD
Sirolimus—Anorexia—Methotrexate—bone cancer	0.000135	0.000521	CcSEcCtD
Sirolimus—Syncope—Doxorubicin—bone cancer	0.000135	0.00052	CcSEcCtD
Sirolimus—Leukopenia—Doxorubicin—bone cancer	0.000134	0.000519	CcSEcCtD
Sirolimus—Confusional state—Epirubicin—bone cancer	0.000134	0.000516	CcSEcCtD
Sirolimus—Palpitations—Doxorubicin—bone cancer	0.000133	0.000513	CcSEcCtD
Sirolimus—Anaphylactic shock—Epirubicin—bone cancer	0.000132	0.000512	CcSEcCtD
Sirolimus—Oedema—Epirubicin—bone cancer	0.000132	0.000512	CcSEcCtD
Sirolimus—Hypotension—Methotrexate—bone cancer	0.000132	0.000511	CcSEcCtD
Sirolimus—Loss of consciousness—Doxorubicin—bone cancer	0.000132	0.00051	CcSEcCtD
Sirolimus—Infection—Epirubicin—bone cancer	0.000132	0.000509	CcSEcCtD
Sirolimus—Cough—Doxorubicin—bone cancer	0.000131	0.000506	CcSEcCtD
Sirolimus—Shock—Epirubicin—bone cancer	0.00013	0.000504	CcSEcCtD
Sirolimus—Nervous system disorder—Epirubicin—bone cancer	0.00013	0.000502	CcSEcCtD
Sirolimus—Thrombocytopenia—Epirubicin—bone cancer	0.00013	0.000501	CcSEcCtD
Sirolimus—Hypertension—Doxorubicin—bone cancer	0.00013	0.000501	CcSEcCtD
Sirolimus—Tachycardia—Epirubicin—bone cancer	0.000129	0.0005	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000129	0.000498	CcSEcCtD
Sirolimus—Skin disorder—Epirubicin—bone cancer	0.000129	0.000497	CcSEcCtD
Sirolimus—Hyperhidrosis—Epirubicin—bone cancer	0.000128	0.000495	CcSEcCtD
Sirolimus—Insomnia—Methotrexate—bone cancer	0.000128	0.000495	CcSEcCtD
Sirolimus—Myalgia—Doxorubicin—bone cancer	0.000128	0.000494	CcSEcCtD
Sirolimus—Arthralgia—Doxorubicin—bone cancer	0.000128	0.000494	CcSEcCtD
Sirolimus—Chest pain—Doxorubicin—bone cancer	0.000128	0.000494	CcSEcCtD
Sirolimus—Anxiety—Doxorubicin—bone cancer	0.000127	0.000492	CcSEcCtD
Sirolimus—Paraesthesia—Methotrexate—bone cancer	0.000127	0.000491	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000127	0.000491	CcSEcCtD
Sirolimus—Discomfort—Doxorubicin—bone cancer	0.000126	0.000488	CcSEcCtD
Sirolimus—Anorexia—Epirubicin—bone cancer	0.000126	0.000488	CcSEcCtD
Sirolimus—Dyspnoea—Methotrexate—bone cancer	0.000126	0.000488	CcSEcCtD
Sirolimus—Somnolence—Methotrexate—bone cancer	0.000126	0.000486	CcSEcCtD
Sirolimus—Dyspepsia—Methotrexate—bone cancer	0.000125	0.000481	CcSEcCtD
Sirolimus—Hypotension—Epirubicin—bone cancer	0.000124	0.000478	CcSEcCtD
Sirolimus—Confusional state—Doxorubicin—bone cancer	0.000124	0.000478	CcSEcCtD
Sirolimus—Decreased appetite—Methotrexate—bone cancer	0.000123	0.000475	CcSEcCtD
Sirolimus—Anaphylactic shock—Doxorubicin—bone cancer	0.000123	0.000474	CcSEcCtD
Sirolimus—Oedema—Doxorubicin—bone cancer	0.000123	0.000474	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Methotrexate—bone cancer	0.000122	0.000472	CcSEcCtD
Sirolimus—Infection—Doxorubicin—bone cancer	0.000122	0.000471	CcSEcCtD
Sirolimus—Pain—Methotrexate—bone cancer	0.000121	0.000468	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000121	0.000466	CcSEcCtD
Sirolimus—Shock—Doxorubicin—bone cancer	0.000121	0.000466	CcSEcCtD
Sirolimus—Nervous system disorder—Doxorubicin—bone cancer	0.00012	0.000464	CcSEcCtD
Sirolimus—Thrombocytopenia—Doxorubicin—bone cancer	0.00012	0.000464	CcSEcCtD
Sirolimus—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	0.00012	0.000758	CbGpPWpGaD
Sirolimus—Insomnia—Epirubicin—bone cancer	0.00012	0.000463	CcSEcCtD
Sirolimus—MTOR—PI3K/AKT activation—EGFR—bone cancer	0.00012	0.000757	CbGpPWpGaD
Sirolimus—Tachycardia—Doxorubicin—bone cancer	0.00012	0.000462	CcSEcCtD
Sirolimus—MTOR—Signaling by ERBB2—MDM2—bone cancer	0.000119	0.000756	CbGpPWpGaD
Sirolimus—Skin disorder—Doxorubicin—bone cancer	0.000119	0.00046	CcSEcCtD
Sirolimus—Paraesthesia—Epirubicin—bone cancer	0.000119	0.00046	CcSEcCtD
Sirolimus—MTOR—DAP12 signaling—MDM2—bone cancer	0.000119	0.000752	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000119	0.000752	CbGpPWpGaD
Sirolimus—MTOR—GAB1 signalosome—EGFR—bone cancer	0.000119	0.000751	CbGpPWpGaD
Sirolimus—Hyperhidrosis—Doxorubicin—bone cancer	0.000118	0.000458	CcSEcCtD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—BRAF—bone cancer	0.000118	0.000748	CbGpPWpGaD
Sirolimus—FGF2—Regulation of Actin Cytoskeleton—EGFR—bone cancer	0.000118	0.000748	CbGpPWpGaD
Sirolimus—FGF2—Downstream signaling of activated FGFR—EGFR—bone cancer	0.000118	0.000748	CbGpPWpGaD
Sirolimus—Dyspnoea—Epirubicin—bone cancer	0.000118	0.000456	CcSEcCtD
Sirolimus—CYP3A7—Metabolism—NDUFA12—bone cancer	0.000118	0.000745	CbGpPWpGaD
Sirolimus—Somnolence—Epirubicin—bone cancer	0.000118	0.000455	CcSEcCtD
Sirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—MDM2—bone cancer	0.000117	0.000741	CbGpPWpGaD
Sirolimus—Anorexia—Doxorubicin—bone cancer	0.000117	0.000451	CcSEcCtD
Sirolimus—Feeling abnormal—Methotrexate—bone cancer	0.000117	0.000451	CcSEcCtD
Sirolimus—Dyspepsia—Epirubicin—bone cancer	0.000117	0.000451	CcSEcCtD
Sirolimus—FGF2—Signaling by ERBB4—EGFR—bone cancer	0.000116	0.000736	CbGpPWpGaD
Sirolimus—MTOR—ErbB1 downstream signaling—EGFR—bone cancer	0.000116	0.000734	CbGpPWpGaD
Sirolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—EGFR—bone cancer	0.000116	0.000734	CbGpPWpGaD
Sirolimus—Gastrointestinal pain—Methotrexate—bone cancer	0.000116	0.000447	CcSEcCtD
Sirolimus—Decreased appetite—Epirubicin—bone cancer	0.000115	0.000445	CcSEcCtD
Sirolimus—FKBP1A—Disease—ENO2—bone cancer	0.000115	0.000728	CbGpPWpGaD
Sirolimus—MTOR—BDNF signaling pathway—JUN—bone cancer	0.000115	0.000725	CbGpPWpGaD
Sirolimus—Hypotension—Doxorubicin—bone cancer	0.000115	0.000443	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Epirubicin—bone cancer	0.000114	0.000442	CcSEcCtD
Sirolimus—MTOR—Signaling by SCF-KIT—MMP9—bone cancer	0.000113	0.000718	CbGpPWpGaD
Sirolimus—Pain—Epirubicin—bone cancer	0.000113	0.000438	CcSEcCtD
Sirolimus—Constipation—Epirubicin—bone cancer	0.000113	0.000438	CcSEcCtD
Sirolimus—Body temperature increased—Methotrexate—bone cancer	0.000112	0.000432	CcSEcCtD
Sirolimus—Abdominal pain—Methotrexate—bone cancer	0.000112	0.000432	CcSEcCtD
Sirolimus—MTOR—Signaling by FGFR in disease—MDM2—bone cancer	0.000112	0.000708	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—MDM2—bone cancer	0.000112	0.000708	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—MDM2—bone cancer	0.000112	0.000708	CbGpPWpGaD
Sirolimus—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000112	0.000432	CcSEcCtD
Sirolimus—FGF2—Downstream signal transduction—EGFR—bone cancer	0.000111	0.000703	CbGpPWpGaD
Sirolimus—Insomnia—Doxorubicin—bone cancer	0.000111	0.000428	CcSEcCtD
Sirolimus—MTOR—Signaling by EGFR—MDM2—bone cancer	0.000111	0.000701	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR—EGFR—bone cancer	0.000111	0.000699	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—JUN—bone cancer	0.00011	0.000698	CbGpPWpGaD
Sirolimus—Paraesthesia—Doxorubicin—bone cancer	0.00011	0.000425	CcSEcCtD
Sirolimus—FGF2—Signaling by ERBB2—EGFR—bone cancer	0.00011	0.000696	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—MDM2—bone cancer	0.00011	0.000695	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—CDK4—bone cancer	0.00011	0.000693	CbGpPWpGaD
Sirolimus—FGF2—DAP12 signaling—EGFR—bone cancer	0.000109	0.000693	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—MDM2—bone cancer	0.000109	0.000692	CbGpPWpGaD
Sirolimus—Dyspnoea—Doxorubicin—bone cancer	0.000109	0.000422	CcSEcCtD
Sirolimus—Feeling abnormal—Epirubicin—bone cancer	0.000109	0.000422	CcSEcCtD
Sirolimus—Somnolence—Doxorubicin—bone cancer	0.000109	0.000421	CcSEcCtD
Sirolimus—FKBP1A—Signaling Pathways—GRM1—bone cancer	0.000108	0.000686	CbGpPWpGaD
Sirolimus—Gastrointestinal pain—Epirubicin—bone cancer	0.000108	0.000419	CcSEcCtD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000108	0.000685	CbGpPWpGaD
Sirolimus—Dyspepsia—Doxorubicin—bone cancer	0.000108	0.000417	CcSEcCtD
Sirolimus—FGF2—Downstream signaling events of B Cell Receptor (BCR)—EGFR—bone cancer	0.000108	0.000683	CbGpPWpGaD
Sirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	0.000107	0.000679	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—DHFR—bone cancer	0.000107	0.000675	CbGpPWpGaD
Sirolimus—Decreased appetite—Doxorubicin—bone cancer	0.000107	0.000412	CcSEcCtD
Sirolimus—SLCO1B1—Metabolism—NT5C3A—bone cancer	0.000106	0.000673	CbGpPWpGaD
Sirolimus—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000106	0.000409	CcSEcCtD
Sirolimus—MTOR—Insulin Signaling—JUN—bone cancer	0.000105	0.000667	CbGpPWpGaD
Sirolimus—Constipation—Doxorubicin—bone cancer	0.000105	0.000405	CcSEcCtD
Sirolimus—Pain—Doxorubicin—bone cancer	0.000105	0.000405	CcSEcCtD
Sirolimus—Abdominal pain—Epirubicin—bone cancer	0.000105	0.000405	CcSEcCtD
Sirolimus—Body temperature increased—Epirubicin—bone cancer	0.000105	0.000405	CcSEcCtD
Sirolimus—MTOR—EGF/EGFR Signaling Pathway—JUN—bone cancer	0.000104	0.00066	CbGpPWpGaD
Sirolimus—Hypersensitivity—Methotrexate—bone cancer	0.000104	0.000403	CcSEcCtD
Sirolimus—EIF4E—Signaling Pathways—SMO—bone cancer	0.000104	0.000658	CbGpPWpGaD
Sirolimus—EIF4E—Metabolism of proteins—MMP2—bone cancer	0.000104	0.000655	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—MDM2—bone cancer	0.000103	0.000655	CbGpPWpGaD
Sirolimus—FGF2—DAP12 interactions—EGFR—bone cancer	0.000103	0.000652	CbGpPWpGaD
Sirolimus—FGF2—Fc epsilon receptor (FCERI) signaling—EGFR—bone cancer	0.000103	0.000652	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR in disease—EGFR—bone cancer	0.000103	0.000652	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—MDM2—bone cancer	0.000103	0.000649	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR—EGFR—bone cancer	0.000102	0.000646	CbGpPWpGaD
Sirolimus—Asthenia—Methotrexate—bone cancer	0.000102	0.000392	CcSEcCtD
Sirolimus—FGF2—Signaling by EGFR in Cancer—EGFR—bone cancer	0.000101	0.00064	CbGpPWpGaD
Sirolimus—Feeling abnormal—Doxorubicin—bone cancer	0.000101	0.00039	CcSEcCtD
Sirolimus—FGF2—Signaling by PDGF—EGFR—bone cancer	0.000101	0.000637	CbGpPWpGaD
Sirolimus—Gastrointestinal pain—Doxorubicin—bone cancer	0.0001	0.000387	CcSEcCtD
Sirolimus—Pruritus—Methotrexate—bone cancer	0.0001	0.000387	CcSEcCtD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—MDM2—bone cancer	9.9e-05	0.000627	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	9.85e-05	0.000624	CbGpPWpGaD
Sirolimus—Hypersensitivity—Epirubicin—bone cancer	9.76e-05	0.000377	CcSEcCtD
Sirolimus—CYP3A7—Metabolism—NT5C3A—bone cancer	9.76e-05	0.000617	CbGpPWpGaD
Sirolimus—MTOR—Senescence and Autophagy in Cancer—TP53—bone cancer	9.74e-05	0.000616	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	9.72e-05	0.000615	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—JUN—bone cancer	9.72e-05	0.000615	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—ATF1—bone cancer	9.69e-05	0.000613	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	9.69e-05	0.000613	CbGpPWpGaD
Sirolimus—Body temperature increased—Doxorubicin—bone cancer	9.69e-05	0.000374	CcSEcCtD
Sirolimus—Abdominal pain—Doxorubicin—bone cancer	9.69e-05	0.000374	CcSEcCtD
Sirolimus—Diarrhoea—Methotrexate—bone cancer	9.68e-05	0.000374	CcSEcCtD
Sirolimus—MTOR—Signaling by NGF—KIT—bone cancer	9.67e-05	0.000612	CbGpPWpGaD
Sirolimus—FGF2—B Cell Activation—EGFR—bone cancer	9.53e-05	0.000603	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—RB1—bone cancer	9.52e-05	0.000603	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—GNA11—bone cancer	9.52e-05	0.000602	CbGpPWpGaD
Sirolimus—Asthenia—Epirubicin—bone cancer	9.5e-05	0.000367	CcSEcCtD
Sirolimus—FGF2—Signaling Pathways—GRM4—bone cancer	9.47e-05	0.000599	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—RGS1—bone cancer	9.47e-05	0.000599	CbGpPWpGaD
Sirolimus—Pruritus—Epirubicin—bone cancer	9.37e-05	0.000362	CcSEcCtD
Sirolimus—Dizziness—Methotrexate—bone cancer	9.36e-05	0.000362	CcSEcCtD
Sirolimus—FGF2—Extracellular matrix organization—MMP9—bone cancer	9.25e-05	0.000586	CbGpPWpGaD
Sirolimus—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	9.21e-05	0.000583	CbGpPWpGaD
Sirolimus—MTOR—Signaling by SCF-KIT—EGFR—bone cancer	9.17e-05	0.00058	CbGpPWpGaD
Sirolimus—FGF2—NGF signalling via TRKA from the plasma membrane—EGFR—bone cancer	9.12e-05	0.000577	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—BRAF—bone cancer	9.09e-05	0.000575	CbGpPWpGaD
Sirolimus—Diarrhoea—Epirubicin—bone cancer	9.06e-05	0.00035	CcSEcCtD
Sirolimus—Hypersensitivity—Doxorubicin—bone cancer	9.03e-05	0.000349	CcSEcCtD
Sirolimus—Vomiting—Methotrexate—bone cancer	9e-05	0.000348	CcSEcCtD
Sirolimus—FGF2—Developmental Biology—MET—bone cancer	8.94e-05	0.000566	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—CDK4—bone cancer	8.94e-05	0.000566	CbGpPWpGaD
Sirolimus—Rash—Methotrexate—bone cancer	8.92e-05	0.000345	CcSEcCtD
Sirolimus—Dermatitis—Methotrexate—bone cancer	8.91e-05	0.000345	CcSEcCtD
Sirolimus—Headache—Methotrexate—bone cancer	8.87e-05	0.000343	CcSEcCtD
Sirolimus—EIF4E—Signaling Pathways—ATF1—bone cancer	8.85e-05	0.00056	CbGpPWpGaD
Sirolimus—Asthenia—Doxorubicin—bone cancer	8.79e-05	0.00034	CcSEcCtD
Sirolimus—MTOR—Downstream signaling of activated FGFR—EGFR—bone cancer	8.77e-05	0.000555	CbGpPWpGaD
Sirolimus—Dizziness—Epirubicin—bone cancer	8.76e-05	0.000338	CcSEcCtD
Sirolimus—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	8.72e-05	0.000552	CbGpPWpGaD
Sirolimus—FGF2—Disease—ENO2—bone cancer	8.71e-05	0.000551	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—EGFR—bone cancer	8.68e-05	0.000549	CbGpPWpGaD
Sirolimus—Pruritus—Doxorubicin—bone cancer	8.67e-05	0.000335	CcSEcCtD
Sirolimus—MTOR—Signaling by ERBB4—EGFR—bone cancer	8.63e-05	0.000546	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—IL3—bone cancer	8.63e-05	0.000546	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—NDUFA12—bone cancer	8.51e-05	0.000539	CbGpPWpGaD
Sirolimus—Vomiting—Epirubicin—bone cancer	8.42e-05	0.000325	CcSEcCtD
Sirolimus—Nausea—Methotrexate—bone cancer	8.41e-05	0.000325	CcSEcCtD
Sirolimus—Diarrhoea—Doxorubicin—bone cancer	8.38e-05	0.000324	CcSEcCtD
Sirolimus—Rash—Epirubicin—bone cancer	8.35e-05	0.000323	CcSEcCtD
Sirolimus—Dermatitis—Epirubicin—bone cancer	8.34e-05	0.000322	CcSEcCtD
Sirolimus—Headache—Epirubicin—bone cancer	8.3e-05	0.000321	CcSEcCtD
Sirolimus—MTOR—Downstream signal transduction—EGFR—bone cancer	8.24e-05	0.000522	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	8.24e-05	0.000521	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	8.22e-05	0.00052	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—GRM1—bone cancer	8.21e-05	0.00052	CbGpPWpGaD
Sirolimus—MTOR—EGF/EGFR Signaling Pathway—EGFR—bone cancer	8.2e-05	0.000519	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—EGFR—bone cancer	8.2e-05	0.000519	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—EGFR—bone cancer	8.16e-05	0.000516	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	8.13e-05	0.000515	CbGpPWpGaD
Sirolimus—MTOR—DAP12 signaling—EGFR—bone cancer	8.12e-05	0.000514	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—MDM2—bone cancer	8.12e-05	0.000514	CbGpPWpGaD
Sirolimus—Dizziness—Doxorubicin—bone cancer	8.1e-05	0.000313	CcSEcCtD
Sirolimus—FGF2—Disease—DHFR—bone cancer	8.08e-05	0.000512	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—EGFR—bone cancer	8e-05	0.000507	CbGpPWpGaD
Sirolimus—Nausea—Epirubicin—bone cancer	7.87e-05	0.000304	CcSEcCtD
Sirolimus—Vomiting—Doxorubicin—bone cancer	7.79e-05	0.000301	CcSEcCtD
Sirolimus—EIF4E—Immune System—KIT—bone cancer	7.79e-05	0.000493	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—TGFBR2—bone cancer	7.73e-05	0.000489	CbGpPWpGaD
Sirolimus—Rash—Doxorubicin—bone cancer	7.73e-05	0.000299	CcSEcCtD
Sirolimus—Dermatitis—Doxorubicin—bone cancer	7.72e-05	0.000298	CcSEcCtD
Sirolimus—Headache—Doxorubicin—bone cancer	7.68e-05	0.000297	CcSEcCtD
Sirolimus—MTOR—Signaling by FGFR in disease—EGFR—bone cancer	7.64e-05	0.000484	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—EGFR—bone cancer	7.64e-05	0.000484	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—EGFR—bone cancer	7.64e-05	0.000484	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—SMO—bone cancer	7.63e-05	0.000483	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—MDM2—bone cancer	7.62e-05	0.000482	CbGpPWpGaD
Sirolimus—FGF2—Immune System—ATF1—bone cancer	7.61e-05	0.000481	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—EGFR—bone cancer	7.57e-05	0.000479	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—EGFR—bone cancer	7.51e-05	0.000475	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—EGFR—bone cancer	7.47e-05	0.000473	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—MMP2—bone cancer	7.46e-05	0.000472	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—KIT—bone cancer	7.43e-05	0.00047	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IL3—bone cancer	7.42e-05	0.000469	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TGFBR2—bone cancer	7.38e-05	0.000467	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—TP53—bone cancer	7.28e-05	0.000461	CbGpPWpGaD
Sirolimus—Nausea—Doxorubicin—bone cancer	7.28e-05	0.000281	CcSEcCtD
Sirolimus—FGF2—Adaptive Immune System—KIT—bone cancer	7.14e-05	0.000452	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	7.09e-05	0.000449	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—EGFR—bone cancer	7.07e-05	0.000447	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—JUN—bone cancer	7.06e-05	0.000447	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—NT5C3A—bone cancer	7.05e-05	0.000446	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—RGS1—bone cancer	7.03e-05	0.000445	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—GRM4—bone cancer	7.03e-05	0.000445	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—EGFR—bone cancer	7.01e-05	0.000444	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—GNA11—bone cancer	6.98e-05	0.000442	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—IGF1R—bone cancer	6.94e-05	0.000439	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—EGFR—bone cancer	6.77e-05	0.000428	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—ATF1—bone cancer	6.49e-05	0.000411	CbGpPWpGaD
Sirolimus—MTOR—Disease—ENO2—bone cancer	6.47e-05	0.000409	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—NDUFA12—bone cancer	6.42e-05	0.000406	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IL3—bone cancer	6.33e-05	0.0004	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—MDM2—bone cancer	6.13e-05	0.000388	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	6.11e-05	0.000387	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—GRM1—bone cancer	6.09e-05	0.000386	CbGpPWpGaD
Sirolimus—MTOR—Disease—DHFR—bone cancer	6e-05	0.00038	CbGpPWpGaD
Sirolimus—FGF2—Disease—TGFBR2—bone cancer	5.86e-05	0.000371	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—MDM2—bone cancer	5.85e-05	0.00037	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—SMO—bone cancer	5.78e-05	0.000366	CbGpPWpGaD
Sirolimus—CYP3A4—Biological oxidations—GSTP1—bone cancer	5.65e-05	0.000357	CbGpPWpGaD
Sirolimus—MTOR—Immune System—ATF1—bone cancer	5.65e-05	0.000357	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—MDM2—bone cancer	5.62e-05	0.000356	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—MMP9—bone cancer	5.61e-05	0.000355	CbGpPWpGaD
Sirolimus—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	5.57e-05	0.000352	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—KIT—bone cancer	5.52e-05	0.000349	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL3—bone cancer	5.51e-05	0.000348	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TGFBR2—bone cancer	5.41e-05	0.000343	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—JUN—bone cancer	5.33e-05	0.000337	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—NT5C3A—bone cancer	5.32e-05	0.000337	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—KIT—bone cancer	5.3e-05	0.000335	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—GNA11—bone cancer	5.29e-05	0.000335	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—KIT—bone cancer	5.27e-05	0.000334	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—EGFR—bone cancer	5.21e-05	0.000329	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IGF1R—bone cancer	5.09e-05	0.000322	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—JUN—bone cancer	5.09e-05	0.000322	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—KIT—bone cancer	5.04e-05	0.000319	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—BRAF—bone cancer	4.96e-05	0.000314	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—ATF1—bone cancer	4.92e-05	0.000311	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IL3—bone cancer	4.8e-05	0.000304	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—BRAF—bone cancer	4.73e-05	0.0003	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—TP53—bone cancer	4.66e-05	0.000295	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—ENO2—bone cancer	4.66e-05	0.000295	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—EGFR—bone cancer	4.53e-05	0.000287	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	4.53e-05	0.000287	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	4.37e-05	0.000276	CbGpPWpGaD
Sirolimus—MTOR—Disease—TGFBR2—bone cancer	4.35e-05	0.000275	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—MDM2—bone cancer	4.34e-05	0.000275	CbGpPWpGaD
Sirolimus—FGF2—Immune System—KIT—bone cancer	4.33e-05	0.000274	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—DHFR—bone cancer	4.32e-05	0.000273	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—SMO—bone cancer	4.29e-05	0.000272	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—ENO2—bone cancer	4.27e-05	0.00027	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—EGFR—bone cancer	4.19e-05	0.000265	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—MDM2—bone cancer	4.17e-05	0.000264	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—MDM2—bone cancer	4.15e-05	0.000263	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TGFBR2—bone cancer	4.1e-05	0.00026	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—GNA11—bone cancer	4.04e-05	0.000256	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—PTGS2—bone cancer	4e-05	0.000253	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—EGFR—bone cancer	4e-05	0.000253	CbGpPWpGaD
Sirolimus—FGF2—Disease—KIT—bone cancer	4e-05	0.000253	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MDM2—bone cancer	3.97e-05	0.000251	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—DHFR—bone cancer	3.97e-05	0.000251	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—NDUFA12—bone cancer	3.96e-05	0.00025	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	3.94e-05	0.000249	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—GNA11—bone cancer	3.93e-05	0.000248	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IGF1R—bone cancer	3.86e-05	0.000244	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—EGFR—bone cancer	3.84e-05	0.000243	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—JUN—bone cancer	3.78e-05	0.000239	CbGpPWpGaD
Sirolimus—FGF2—Disease—BRAF—bone cancer	3.76e-05	0.000238	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—GNA11—bone cancer	3.71e-05	0.000235	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—KIT—bone cancer	3.69e-05	0.000234	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—CYP3A4—bone cancer	3.66e-05	0.000232	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—ATF1—bone cancer	3.65e-05	0.000231	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.64e-05	0.00023	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IL3—bone cancer	3.56e-05	0.000225	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—BRAF—bone cancer	3.47e-05	0.00022	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—JUN—bone cancer	3.45e-05	0.000218	CbGpPWpGaD
Sirolimus—FGF2—Immune System—MDM2—bone cancer	3.41e-05	0.000216	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CYP3A4—bone cancer	3.36e-05	0.000213	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MMP9—bone cancer	3.35e-05	0.000212	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—NT5C3A—bone cancer	3.28e-05	0.000208	CbGpPWpGaD
Sirolimus—MTOR—Immune System—KIT—bone cancer	3.21e-05	0.000203	CbGpPWpGaD
Sirolimus—FGF2—Disease—MDM2—bone cancer	3.15e-05	0.000199	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—GSTP1—bone cancer	3.13e-05	0.000198	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	3.1e-05	0.000196	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ENO2—bone cancer	3.09e-05	0.000196	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TGFBR2—bone cancer	3.04e-05	0.000193	CbGpPWpGaD
Sirolimus—FGF2—Disease—PTGS2—bone cancer	3.03e-05	0.000192	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—EGFR—bone cancer	2.97e-05	0.000188	CbGpPWpGaD
Sirolimus—MTOR—Disease—KIT—bone cancer	2.97e-05	0.000188	CbGpPWpGaD
Sirolimus—FGF2—Immune System—JUN—bone cancer	2.96e-05	0.000188	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MDM2—bone cancer	2.91e-05	0.000184	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—GSTP1—bone cancer	2.87e-05	0.000182	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—DHFR—bone cancer	2.87e-05	0.000181	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IGF1R—bone cancer	2.86e-05	0.000181	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—EGFR—bone cancer	2.85e-05	0.00018	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—EGFR—bone cancer	2.84e-05	0.00018	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—KIT—bone cancer	2.8e-05	0.000177	CbGpPWpGaD
Sirolimus—MTOR—Disease—BRAF—bone cancer	2.79e-05	0.000176	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—EGFR—bone cancer	2.71e-05	0.000171	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GNA11—bone cancer	2.68e-05	0.00017	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—BRAF—bone cancer	2.63e-05	0.000166	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	2.6e-05	0.000164	CbGpPWpGaD
Sirolimus—MTOR—Immune System—MDM2—bone cancer	2.53e-05	0.00016	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—JUN—bone cancer	2.53e-05	0.00016	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MMP9—bone cancer	2.46e-05	0.000156	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CYP3A4—bone cancer	2.43e-05	0.000154	CbGpPWpGaD
Sirolimus—MTOR—Disease—MDM2—bone cancer	2.34e-05	0.000148	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ENO2—bone cancer	2.33e-05	0.000148	CbGpPWpGaD
Sirolimus—FGF2—Immune System—EGFR—bone cancer	2.33e-05	0.000147	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TP53—bone cancer	2.28e-05	0.000144	CbGpPWpGaD
Sirolimus—MTOR—Disease—PTGS2—bone cancer	2.25e-05	0.000143	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MDM2—bone cancer	2.2e-05	0.00014	CbGpPWpGaD
Sirolimus—MTOR—Immune System—JUN—bone cancer	2.2e-05	0.000139	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—DHFR—bone cancer	2.16e-05	0.000137	CbGpPWpGaD
Sirolimus—FGF2—Disease—EGFR—bone cancer	2.15e-05	0.000136	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—KIT—bone cancer	2.08e-05	0.000131	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GSTP1—bone cancer	2.08e-05	0.000131	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GNA11—bone cancer	2.02e-05	0.000128	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—EGFR—bone cancer	1.99e-05	0.000126	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—BRAF—bone cancer	1.95e-05	0.000124	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—JUN—bone cancer	1.92e-05	0.000121	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MMP9—bone cancer	1.86e-05	0.000118	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CYP3A4—bone cancer	1.83e-05	0.000116	CbGpPWpGaD
Sirolimus—MTOR—Immune System—EGFR—bone cancer	1.73e-05	0.000109	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TP53—bone cancer	1.67e-05	0.000106	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MDM2—bone cancer	1.64e-05	0.000104	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PTGS2—bone cancer	1.62e-05	0.000103	CbGpPWpGaD
Sirolimus—MTOR—Disease—EGFR—bone cancer	1.6e-05	0.000101	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GSTP1—bone cancer	1.57e-05	9.92e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—EGFR—bone cancer	1.51e-05	9.53e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PTGS2—bone cancer	1.49e-05	9.42e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ENO2—bone cancer	1.44e-05	9.09e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—JUN—bone cancer	1.42e-05	9e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MMP9—bone cancer	1.38e-05	8.75e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—DHFR—bone cancer	1.33e-05	8.43e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TP53—bone cancer	1.26e-05	8e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GNA11—bone cancer	1.25e-05	7.88e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—EGFR—bone cancer	1.12e-05	7.07e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PTGS2—bone cancer	1.08e-05	6.81e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GSTP1—bone cancer	9.66e-06	6.11e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TP53—bone cancer	9.39e-06	5.94e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PTGS2—bone cancer	8.12e-06	5.14e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PTGS2—bone cancer	5e-06	3.17e-05	CbGpPWpGaD
